The new TB vaccine “MTBVAC” is manufactured and developed by Biofabri in close collaboration with the University of Zaragoza, IAVI and the Tuberculosis Vaccine Initiative (TBVI).
“This agreement between Bharat Biotech and Biofabri would guarantee the global production and supply of the future vaccine in more than 70 countries with a high TB incidence, such as India, which has the highest TB burden in the world at 25 percent in any case” , according to the company.
Krishna Ella, Chairman and Managing Director of Bharat Biotech said, “We are proud to announce this partnership with BioFabri in which MTBVAC can become a global TB vaccine.”
Bharat Biotech chose this vaccine candidate due to its advanced stage of clinical development as well as promising results from Phase I and Phase II clinical trials, he added.
The company announced that phase III clinical trials are scheduled to start in the second half of 2022 in Senegal, South Africa and Madagascar.
Biofabri CEO Esteban Rodriguez said the agreement with Bharat Biotech is a milestone in the MTBVAC project.
From day one, the company’s goal has been to make a vaccine available to everyone at affordable prices in middle- and low-income countries where the incidence of tuberculosis is high, Rodriguez added.
“The contract signed with Bharat Biotech ensures that our vaccine reaches countries such as India, Indonesia, the Philippines, Pakistan and South Africa, among others, where tuberculosis is a public health problem due to its high incidence,” Rodriguez said.